Pricing Log in Create free account
Friday 6 November 2026 Export OFIX’s income statement to Excel — free account

ORTHOFIX MEDICAL INC.

OFIX Healthcare Medical Devices

ORTHOFIX MEDICAL INC.’s revenue for fiscal 2025 (year ended December 2025) was $822.3 million, up 2.85% from fiscal 2024.

Revenue
+3.85%
EPS
−8.33%
Free cash flow
−516.6%
Total debt
+34.4%

Quarter to June 2026, against a year earlier

7.99 0.93 −10.43%
Market cap
$363.3M
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
1.29
Beneish M
−3.19
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 6.82
Sold, $m 6.60
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — 1 1 — 2 — — — 1 — —
Sell — 2 — 8 1 1 1 — 2 1 1 1
Insider Ownership 1.63%

Capital & Financial Ratios $m

Size
Market Cap 363.33
Revenue ttm 833.19
Net income ttm (61.72)
Free cash flow ttm (27.82)
Net debt Q 130.09
Valuation
P/E 0.00
Forward P/E (7.72) (negative: loss-making)
Price / sales 0.43
Forward P/S Powerpack
Price / FCF 0.00
Price / book 0.84
Financial health
Current ratio Q 2.84 (at or above 1.5: strong)
Debt / equity Q 0.55
Interest coverage Q (1.34)
Growth
Revenue growth Q +3.85% (above 0%: growing)
Operating income growth Q +49.17% (above 0%: growing)
EPS, this year +49.57% (at or above 15%: strong)
EPS, next year A +19.57% (at or above 15%: strong)
Revenue, next year A +3.51%
EPS, past 5 yrs —
EPS, next 5 yrs A +35.00% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 0.6×, against a ten-year median of 1.3×; over the ten years it ranged from 0.6× in 2026 to 2.5× in 2018.
P/S against its own 10 years 0.22%
10-year low 10-year high
P/B against its own 10 years 4.22%
10-year low 10-year high
EV/Sales against its own 10 years 0.70%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 38 86 85 104
Receivables 128 135 136 136
Inventory 222 189 172 184
Other — — — —
420 433 417 446
2023 2024 2025 Q'26
Payables 58 49 58 64
ST’ Debt 1 — — —
Other 105 119 111 93
165 169 170 157

Compound Annual Growth %

10y 5y 3y
Sales 7.57% 15.13% 21.30%
Cash Flow (2.65%) (14.80%) 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 4.48% 4.75% 10.14%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.03 Actual 0.07

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 0.12 0.20 Beat by 0.08
Q4 FY25 0.44 0.26 Miss by 0.18
Q1 FY26 −0.29 −0.12 Beat by 0.17
Q2 FY26 −0.03 0.07 Beat by 0.10
Q3 FY26 0.11 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.52) (0.39) — — —
’25 (1.35) (0.36) (0.57) (0.06) (2.33)
’24 (0.95) (0.88) (0.71) (0.75) (3.30)
’23 (1.71) (1.07) (0.77) (0.59) (4.12)
’22 (0.22) 0.12 (0.53) (0.35) (0.98)
’21 (0.30) 0.12 (0.11) (1.65) (1.95)
’20 1.32 (0.96) 0.24 (0.48) 0.13
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 197 211 — — —
’25 194 203 206 220 822
’24 189 199 197 216 799
’23 175 187 184 200 747
’22 106 118 114 122 461
’21 106 121 112 125 464
’20 105 73 111 118 407
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (18) (6) — — —
’25 (18) 12 12 28 33
’24 (19) 9 12 24 26
’23 (34) (6) 0 (7) (46)
’22 (8) (5) (1) 2 (12)
’21 2 (2) 6 12 18
’20 12 18 22 22 74
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (28) (19) — — —
’25 (25) 5 2 17 (1)
’24 (29) (1) 6 15 (9)
’23 (46) (18) (23) (22) (108)
’22 (14) (13) (6) (4) (35)
’21 (3) (8) 3 4 (1)
’20 6 13 19 10 50
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 410 434 453 460 407 464 461 747 799 822 833 +8.0% 851 874 918 +3.7%
Gross margin, % 78.56 78.55 78.67 78.13 74.94 75.26 73.18 65.13 68.28 68.83 71.31 (9.7) pt
EBT 19 36 23 (27) 0 (13) (18) (149) (124) (91) (60) n/m
EBT margin, % 4.64 8.39 5.05 (5.88) (0.09) (2.91) (3.84) (19.91) (15.49) (11.04) (7.24) (15.7) pt
Net income 3 6 14 (28) 3 (38) (20) (151) (126) (92) (62) n/m
Per share, $
Per share, $ Revenue 22.59 23.95 24.50 24.33 21.10 23.59 22.97 20.33 20.97 20.76 20.37 (0.9%)
Earnings 0.17 0.34 0.73 (1.51) 0.13 (1.95) (0.98) (4.12) (3.30) (2.33) (1.54) n/m
Cash flow 3.26 2.15 2.70 1.69 3.85 0.94 (0.58) (1.25) 0.68 0.84 0.40 (14.0%)
Capex (1.01) (0.91) (0.90) (1.09) (1.26) (0.99) (1.15) (1.69) (0.91) (0.87) (1.08) (1.6%)
Free cash flow 2.25 1.24 1.80 0.61 2.59 (0.06) (1.73) (2.94) (0.24) (0.03) (0.68) n/m
Book value 14.52 16.37 18.14 17.33 18.52 17.11 16.80 16.30 13.19 11.36 10.49 (2.7%)
Shares, m 18 18 18 19 19 20 20 37 38 40 40 +9.1%
Valuation, ×
Valuation, × P/E 209.00 160.41 71.90 0.00 330.62 0.00 0.00 0.00 0.00 0.00 0.00 77.2
P/S 1.57 2.28 2.14 1.90 2.04 1.32 0.93 0.65 0.83 0.73 0.43 1.4
P/B 2.45 3.33 2.89 2.66 2.32 1.82 1.27 0.81 1.32 1.33 0.84 2.0
EV/Sales 1.49 2.14 2.03 1.79 1.86 1.18 0.87 0.75 0.95 0.85 0.60 1.4
EV/FCF 15.72 49.20 29.11 82.69 15.65 (187.64) (10.83) (5.06) (66.79) (193.86) (16.50) (27.2)
Cash, $m
Cash, $m Operating cash flow 59 39 50 32 74 18 (12) (46) 26 33 16 (6.2%)
Capex (18) (16) (17) (21) (24) (20) (23) (62) (35) (35) (44) +7.3%
Free cash flow 41 22 33 12 50 (1) (35) (108) (9) (1) (28) n/m
Balance, $m
Balance, $m Working capital 111 172 159 176 166 164 172 255 265 246 289 +9.3%
Net debt (54) (81) (72) (48) (72) (64) (29) 75 89 89 130 n/m
Shareholders’ equity 263 297 335 328 357 337 337 599 503 450 429 +6.1%
Returns, %
Returns, % ROA 0.79 1.60 3.17 (5.92) 0.49 (7.66) (4.22) (21.88) (13.86) (10.57) (7.22) (11.4) pt
ROIC 6.28 11.84 7.15 (4.19) (1.37) (1.90) (2.70) (12.90) (8.93) (9.44) (4.37) (15.7) pt
ROE 1.10 2.22 4.37 (8.59) 0.74 (11.06) (5.86) (32.36) (22.87) (19.34) (13.91) (20.4) pt
People
People Employees 938 858 954 1,055 1,036 1,087 1,092 1,634 1,616 1,605 — +6.1%
Revenue/emp, $m 0.44 0.51 0.47 0.44 0.39 0.43 0.42 0.46 0.49 0.51 — +1.8%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

ORTHOFIX MEDICAL INC. vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
BWAY Brainsway Ltd. Sponsored ADR $427.1M 21.2× — (loss-making) +35.43% (above 0%: growing) +40.00% (above 0%: growing) −51.68% (below 0%: shrinking) 74.62% 13.98% Compare
SI Shoulder Innovations, Inc. $424.1M — (loss-making) — (loss-making) +37.73% (above 0%: growing) n/m +38.63% (above 0%: growing) 78.47% (46.92%) Compare
MASS 908 Devices Inc. $419.5M — (loss-making) — (loss-making) +23.31% (above 0%: growing) n/m +150.95% (above 0%: growing) 51.90% (79.69%) Compare
RCEL Avita Medical Inc. $389.5M — (loss-making) — (loss-making) +53.05% (above 0%: growing) n/m +86.66% (above 0%: growing) 84.02% (17.95%) Compare
SSII SS Innovations International, Inc. $380.9M — (loss-making) — (loss-making) +39.39% (above 0%: growing) n/m −16.62% (below 0%: shrinking) 50.94% (16.29%) Compare
MOBI Mobia Medical, Inc $375.5M — (loss-making) — (loss-making) +175.85% (above 0%: growing) n/m −18.01% (below 0%: shrinking) 83.25% (118.67%) Compare
OFIX ORTHOFIX MEDICAL INC. $363.3M — (loss-making) — (loss-making) +3.85% (above 0%: growing) n/m −516.58% (below 0%: shrinking) 70.97% (3.86%)
VMD Viemed Healthcare, Inc. $343.2M 22.0× 23.4× +12.18% (above 0%: growing) +33.33% (above 0%: growing) −67.55% (below 0%: shrinking) 57.26% 0.00% Compare
CV CapsoVision, Inc. $329.9M — (loss-making) — (loss-making) +9.89% (above 0%: growing) n/m −84.44% (below 0%: shrinking) 51.36% (208.07%) Compare
Median of peers $385.2M — — +36.58% — −17.31% 65.94% (32.43%)

All 149 Medical Devices stocks →

Pay and ownership Proxy statement filed 29 April 2026

Ownership

Directors and executive officers, together 2.70%
Engine Capital Management, L.P. 10.90%
Juniper Investments Company LLC 9.40%
Rubric Capital Management LP 9.10%
BlackRock, Inc. 7.40%
Armistice Capital, LLC 6.60%
Paradigm Capital Management, Inc. Nine Elk Street Albany, NY 6.30%
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

ORTHOFIX MEDICAL INC. (OFIX) Latest News

23 Oct

Impact 3 · · Business Wire

12 Oct

Impact 4 · · cfodive.com

24 Aug

Impact 3 ·

15 Aug

Impact 3 · · MarketBeat

12 Aug

Impact 3 · · The Motley Fool transcript

5 Aug

Impact 4 · transcript
Impact 3 · · MarketBeat
Impact 3 · · Moby transcript
Impact 3 ·
Impact 3 ·

23 Jul

Impact 4 ·

18 Jun

Impact 4 ·

4 Jun

Impact 4 · · Simply Wall St.

16 May

Impact 4 · · Simply Wall St.

8 May

Impact 3 · · Simply Wall St.

6 May

Impact 4 · · Business Wire

5 May

Impact 4 · · Moby
Impact 4 · · The Motley Fool transcript
Impact 3 · · MarketBeat
Impact 3 · · Business Wire

25 Apr

Impact 4 · · Simply Wall St.

9 Apr

Impact 3 · · Business Wire

14 Mar

Impact 3 · · Simply Wall St.

2 Mar

Impact 3 · · Insider Monkey

26 Feb

Impact 4 ·

24 Feb

Impact 4 · · Moby
Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · The Motley Fool transcript
Impact 3 · · Zacks
stockrow.com/OFIX · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com